News
SC0062 is potentially a best-in-class ETA receptor-selective antagonist. About the Phase 2 Clinical Study of SC0062 (CTR20230689) ...
SC0062 is potentially a best-in-class ETA receptor-selective antagonist. About the Phase 2 Clinical Study of SC0062 (CTR20230689) ...
SC0062 is potentially a best-in-class ETA receptor-selective antagonist. About the Phase 2 Clinical Study of SC0062 (CTR20230689) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback